Intracellular News and Research

RSS

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Niiki Pharma Inc. announced interim results from the ongoing Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class transferrin targeted small molecule that down-regulates GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.

20 Sep 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have made a landmark discovery in the battle against the rapid spread of aggressive cancers associated with PRL-3 oncoprotein.

9 Sep 2011

Study: Protein's structural arrangement can change its signaling function

In a joint study, scientists from the California and Florida campuses of The Scripps Research Institute have shown that changes in a protein's structure can change its signaling function and they have pinpointed the precise regions where those changes take place.

8 Sep 2011

Elevating free radical levels suppresses appetite in obese mice

Obesity is growing at alarming rates worldwide, and the biggest culprit is overeating. In a study of brain circuits that control hunger and satiety, Yale School of Medicine researchers have found that molecular mechanisms controlling free radicals-molecules tied to aging and tissue damage-are at the heart of increased appetite in diet-induced obesity.

29 Aug 2011

Scientists discover nanoparticles can disrupt intracellular transport pathways

Scientists at the Centre of Cancer Biomedicine at the Norwegian Radium Hospital are the first to show that uptake and accumulation of nanoparticles in cells can disrupt important intracellular transport pathways.

24 Aug 2011

NPL scientists mimick the ways viruses infect human cells and deliver genetic material

Scientists at the National Physical Laboratory (NPL) have mimicked the ways viruses infect human cells and deliver their genetic material. The research hopes to apply the approach to gene therapy - a therapeutic strategy to correct defective genes such as those that cause cancer.

12 Aug 2011

Scientists identify small molecule inhibitors of cellular uptake

Scientists from Freie Universität Berlin and the NeuroCure Cluster of Excellence led by biochemist Volker Haucke in collaboration with colleagues from Australia and the Leibniz Institute for Molecular Pharmacology in Berlin have developed small molecules that inhibit the internalization of important signaling molecules but also of pathogenic organisms such as the immunodeficiency virus and bacteria into cells.

5 Aug 2011

Azithromycin may predispose cystic fibrosis patients to mycobacterial infection

Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin.

2 Aug 2011

New protein discovery could help develop intracellular biologic drugs

Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins-.

29 Jul 2011

Scientists reveal complete three-dimensional atomic structure of an activated GPCR

G protein-coupled receptors (GPCRs) are popular drug targets, accounting for about one-third of approved drugs and many hundreds of drugs currently in development. They act as molecular switches that transduce extracellular signals by activating heterotrimeric G proteins located at the inside of the cell.

27 Jul 2011

Substances found in cigarette smoke damage blood vessels' endothelial cells

A research term headed by David Bernhard from the University Department of Surgery at the Medical University of Vienna has found out that substances found in cigarette smoke lead to blood vessels' endothelial cells constantly digesting themselves.

26 Jul 2011

Symposium papers highlight role of oxidative stress in cardiovascular disease

Recent years have seen major advances in understanding of the health effects of oxidative stress—including its potential to cause injury to the cardiovascular system. A series of expert updates on the role of oxidative stress in heart failure, atherosclerosis, and other cardiovascular diseases appears in a special symposium in the August issue of The American Journal of the Medical Sciences, official journal of the Southern Society for Clinical Investigation.

26 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

Researchers characterise protein complex linked to malaria and toxoplasmosis

Maryse Lebrun, Research Director at Inserm, and her fellow researchers at the Laboratoire Dynamique des interactions membranaires normales et pathologiques, have characterised a protein complex that allows the agents that cause malaria and toxoplasmosis to infect host cells.

25 Jul 2011

New details about how dendritic cells regulate fate of naive T cells

St. Jude Children's Research Hospital scientists show that the molecule serves as a bridge between the two arms of the immune system that provides a new mechanism guiding T cell differentiation.

25 Jul 2011

Strategies toxins use to invade human host cells

Toxins produced by plants and bacteria pose a significant threat to humans, as emphasized by the recent effects of cucumber-borne Shiga toxin in Germany. Now, new research published on July 21st by the Cell Press journal Developmental Cell provides a clearer view of the combination of similar and divergent strategies that different toxins use to invade a human host cell.

22 Jul 2011